The protective role of immunoglobulins in fungal infections and inflammation
2015 (English)In: Seminars in Immunopathology, ISSN 1863-2297, E-ISSN 1863-2300, Vol. 37, no 2, 187-197 p.Article, review/survey (Refereed) Published
Increased incidence of fungal infections in the immunocompromised individuals and fungi-mediated allergy and inflammatory conditions in immunocompetent individuals is a cause of concern. Consequently, there is a need for efficient therapeutic alternatives to treat fungal infections and inflammation. Several studies have demonstrated that antibodies or immunoglobulins have a role in restricting the fungal burden and their clearance. However, based on the data from monoclonal antibodies, it is now evident that the efficacy of antibodies in fungal infections is dependent on epitope specificity, abundance of protective antibodies, and their isotype. Antibodies confer protection against fungal infections by multiple mechanisms that include direct neutralization of fungi and their antigens, inhibition of growth of fungi, modification of gene expression, signaling and lipid metabolism, causing iron starvation, inhibition of polysaccharide release, and biofilm formation. Antibodies promote opsonization of fungi and their phagocytosis, complement activation, and antibody-dependent cell toxicity. Passive administration of specific protective monoclonal antibodies could also prove to be beneficial in drug resistance cases, to reduce the dosage and associated toxic symptoms of anti-fungal drugs. The longer half-life of the antibodies and flexibilities to modify their structure/forms are additional advantages. The clinical data obtained with two monoclonal antibodies should incite interests in translating pre-clinical success into the clinics. The anti-inflammatory and immunoregulatory role of antibodies in fungal inflammation could be exploited by intravenous immunoglobulin or IVIg.
Place, publisher, year, edition, pages
Springer Verlag (Germany) , 2015. Vol. 37, no 2, 187-197 p.
Fungi; Immunoglobulin; Inflammation; Aspergillus; Candida; Intravenous immunoglobulin; Therapy-Natural antibodies
IdentifiersURN: urn:nbn:se:liu:diva-115317DOI: 10.1007/s00281-014-0466-0ISI: 000349394700012PubMedID: 25404121OAI: oai:DiVA.org:liu-115317DiVA: diva2:795097
Funding Agencies|European Community [260338 ALLFUN, ANR-10-BLAN-1309 HYDROPHOBIN]; Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Universite Pierre et Marie Curie; Universite Paris Descartes2015-03-132015-03-132016-01-09